Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $159.00

Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price increased by SVB Leerink from $138.00 to $159.00 in a research note issued to investors on Tuesday, Benzinga reports. They currently have a market perform rating on the biopharmaceutical company’s stock.

A number of other analysts also recently weighed in on the stock. BMO Capital Markets reissued an outperform rating and set a $234.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday. Morgan Stanley lifted their price objective on shares of Alnylam Pharmaceuticals from $164.00 to $250.00 and gave the company an equal weight rating in a research note on Tuesday. Royal Bank of Canada boosted their price target on shares of Alnylam Pharmaceuticals from $235.00 to $250.00 and gave the stock an outperform rating in a research report on Tuesday. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a hold rating to a buy rating in a research report on Monday, April 29th. Finally, Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $161.00 to $207.00 and gave the stock an equal weight rating in a research note on Tuesday. Eight equities research analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of Moderate Buy and an average target price of $245.14.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $247.00 on Tuesday. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $252.87. The company has a 50-day moving average of $157.89 and a 200-day moving average of $164.23. The company has a market cap of $31.24 billion, a P/E ratio of -92.16 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.23. The firm had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. During the same period last year, the business earned ($1.40) EPS. The firm’s revenue was up 54.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals will post -3.75 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, Director Amy W. Schulman sold 21,700 shares of the company’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the completion of the transaction, the director now directly owns 8,436 shares in the company, valued at $1,253,589.60. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, Director Amy W. Schulman sold 21,700 shares of the business’s stock in a transaction that occurred on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total transaction of $3,224,620.00. Following the sale, the director now directly owns 8,436 shares in the company, valued at $1,253,589.60. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 1,198 shares of the company’s stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $276,726.02. Following the completion of the sale, the executive vice president now owns 14,181 shares in the company, valued at $3,275,669.19. The disclosure for this sale can be found here. Insiders sold a total of 67,357 shares of company stock worth $13,436,711 over the last three months. 1.50% of the stock is currently owned by insiders.

Institutional Trading of Alnylam Pharmaceuticals

Large investors have recently made changes to their positions in the business. Allspring Global Investments Holdings LLC grew its holdings in shares of Alnylam Pharmaceuticals by 572.0% during the first quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 143 shares during the last quarter. Quent Capital LLC grew its holdings in shares of Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 123 shares in the last quarter. Anchor Investment Management LLC bought a new position in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $38,000. Altitude Crest Partners Inc. bought a new position in Alnylam Pharmaceuticals in the first quarter valued at approximately $30,000. Finally, GAMMA Investing LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $52,000. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.